Pharma commercial intelligence, news & analysis

Evaluate gives you the understanding and time you need to drive better decisions.

When you partner with Evaluate, our constantly expanding solutions and transparent methodologies and datasets are instantly at your disposal, along with expert, personalised support.

Evaluate gives you the time and confidence to turn understanding into insight, and insight into action.

How we can help you

Market Reports

Thought Leadership

Read our wide range of complimentary market reports covering sector performance and valuation, market trends and global forecasts, including our annual EvaluatePharma World Preview.

OUR PRODUCTS

EvaluatePharma

Get a global view of the pharmaceutical market’s past, present and future performance with consensus forecasts to 2024 and the first single view of the risk and reward of the R&D landscape from EvaluatePharma Vision.

OUR SERVICES

Custom Solutions

Improve your strategic decision-making with customised solutions that draw on our team of industry experts and trusted commercial intelligence.

October 15, 2018

Real threat to Opdivo’s small-cell chances will come from elsewhere

Bristol-Myers Squibb's Opdivo has flunked the Checkmate-331 study, but this is unlikely to lead to the revoking of US approval in this lung cancer setting.